Limaca Medical
Electro-mechanically Driven Endoscopic Ultrasound-guided Biopsy
Company Overview
Snapshot
Founded in January 2015 by Assaf Klein and Iyad Khamaysi, Limaca Medical operates with 1–10 employees. The company has raised $1.25 million across two funding rounds from four investors. In November 2020, Limaca Medical secured $1.25 million to advance precision medicine through improved biopsies.
Business overview
Limaca Medical is a Health Tech & Life Sciences company focused on developing advanced medical technologies for improved diagnosis of gastrointestinal system tumors. Its core product, KORA, is an electro-mechanically driven endoscopic ultrasound-guided biopsy device designed to obtain higher-quality core tissue for superior histopathologic analysis and enhanced diagnostic accuracy. The company initially targets pancreatic tumors, with future expansion plans into liver and lung cancer markets. Limaca Medical operates within the medical devices, diagnostics, and personalized medicine sectors, serving hospitals and healthcare providers globally.
Strategic signal
In November 2024, Limaca Medical's Precision-GI™ received CMS Transitional Pass-Through (TPT) payment. This designation is a significant market validation, indicating that the Centers for Medicare & Medicaid Services recognize the device's innovative nature and potential to improve patient care, thereby facilitating broader adoption and reimbursement in the US healthcare system. This signals strong commercial momentum and regulatory acceptance for investors.
Log in to access full profile ›Company Intelligence Q&A
- What is Limaca Medical's primary product?
- Limaca Medical's primary product is KORA, an electro-mechanically driven endoscopic ultrasound-guided biopsy device designed to improve the diagnosis of gastrointestinal system tumors by obtaining higher-quality core tissue.
- When did Limaca Medical receive FDA Breakthrough Device designation?
- Limaca Medical received FDA Breakthrough Device designation for its Precision-GI product in May 2022.
- When did Limaca Medical announce its partnership in Japan?
- Limaca Medical announced a partnership with HekaBio in Japan on May 16, 2022, to distribute its Precision-GI device in the Japanese market.
- What significant payment status did Limaca Medical's Precision-GI receive?
- In November 2024, Limaca's Precision-GI was granted CMS Transitional Pass-Through (TPT) payment, facilitating its reimbursement in the US market.
- When did Limaca Medical launch its Precision-GI device in the US market?
- Limaca Medical launched its Precision-GI endoscopic automated motorized EUS biopsy device in the US market in February 2025.